24 September 2013 | News | By BioSpectrum Bureau
iSonea launches its AirSonea wheeze monitoring device in the Australia. The device uses the firm's proprietary Acoustic Respiratory Monitoring (ARM) technology
Singapore: Australian medical technology company, iSonea, launched AirSonea wheeze monitoring device, in the Australian market. The device is intended for people, who are diagnosed with asthma.
The digital device enables wheeze monitoring via smartphones for the first time, using the company's proprietary Acoustic Respiratory Monitoring (ARM) technologies.
â€œFor the first time in nearly 50 years, we have a new monitoring technology available for people suffering from asthma,â€ said, Mr Michael Thomas, CEO, iSonea. â€œInvestors in our company are participating in the most exciting advancement in decades in respiratory mobile health technology. The AirSonea is a global product and builds on our company's existing platform technology, the AsthmaSense app. This new product heralds the second wave of mobile health in the asthma space.â€
The AirSonea is a handheld device that turns a patient's smartphone into a portable wheeze monitor. AirSonea is held against the windpipe near the base of the throat to record breathing sounds. These sounds are automatically transmitted to a cloud-based site and analysed with the company's ARM wheeze detection algorithms and software.
AirSonea enables people with asthma to monitor their wheeze anywhere, at any time. It also provides objective data to help doctors with patient reviews. The device has been listed on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA).